Windtree Therapeutics (WINT) announces that the United States Patent and Trademark Office has issued an istaroxime patent for the United States – application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.” Acute heart failure, or AHF, impacts millions of patients globally and istaroxime has previously completed two positive Phase 2 AHF studies and two positive early cardiogenic shock studies caused by acute heart failure.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree announces istaroxime Phase 2 study hit enrollment target
- Windtree Therapeutics CFO Resignation and Leadership Shift
- Windtree Therapeutics Receives Nasdaq Deficiency Letter
- Windtree Therapeutics announces istaroxime Phase 2 study called SEISMiC B
- Windtree Therapeutics Raises $3.9M Through Note Agreements